Catherine Madigan, M.D.

Catherine Madigan, M.D.

Chief Medical OfficeratSyndax Pharmaceuticals· In proxies 2022–2023

Pay in FY2023+6% from the year before · Syndax Pharmaceuticals stock -15.1% the same year

Catherine Madigan, M.D. was paid $2.8M in FY2023 (Dec), up 6%. Syndax Pharmaceuticals stock fell 15.1% that year.

Pay$100 in the stock at the end of FY21 → $99
Pay is from the Summary Compensation Table of each Syndax Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Syndax PharmaceuticalsPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role -35%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?